-
1
-
-
33748116898
-
Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study
-
Palella FJ, Jr., Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
-
(2006)
J Acquir Immune Defic Syndr
, vol.43
, pp. 27-34
-
-
Palella Jr., F.J.1
Baker, R.K.2
Moorman, A.C.3
-
2
-
-
0038502358
-
Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: A 5-year cohort study
-
Lucas GM, Chaisson RE, Moore RD. Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study. J Acquir Immune Defic Syndr 2003; 33: 321-8.
-
(2003)
J Acquir Immune Defic Syndr
, vol.33
, pp. 321-328
-
-
Lucas, G.M.1
Chaisson, R.E.2
Moore, R.D.3
-
3
-
-
0344760902
-
-
Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. December 1, 1-161. Available at
-
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
-
(2009)
Guidelines For the Use of Antiretroviral Agents In HIV-1-infected Adults and Adolescents
-
-
-
4
-
-
34047207229
-
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials
-
Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169-78.
-
(2007)
Lancet
, vol.369
, pp. 1169-1178
-
-
Clotet, B.1
Bellos, N.2
Molina, J.M.3
-
5
-
-
33746576313
-
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1- infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials
-
Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1- infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368: 466-75.
-
(2006)
Lancet
, vol.368
, pp. 466-475
-
-
Hicks, C.B.1
Cahn, P.2
Cooper, D.A.3
-
6
-
-
34247869104
-
Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs control protease inhibitor in the POWER and RESIST trials
-
Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs control protease inhibitor in the POWER and RESIST trials. HIV Med 2007; 8: 259-64.
-
(2007)
HIV Med
, vol.8
, pp. 259-264
-
-
Hill, A.1
Moyle, G.2
-
7
-
-
54849146700
-
Maraviroc for previously treated patients with R5 HIV-1 infection
-
Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-41.
-
(2008)
N Engl J Med
, vol.359
, pp. 1429-1441
-
-
Gulick, R.M.1
Lalezari, J.2
Goodrich, J.3
-
8
-
-
52449097524
-
Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection
-
Montaner J, Yeni P, Clumeck NN, et al. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection. Clin Infect Dis 2008; 47: 969-78.
-
(2008)
Clin Infect Dis
, vol.47
, pp. 969-978
-
-
Montaner, J.1
Yeni, P.2
Clumeck, N.N.3
-
9
-
-
47949114939
-
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
-
Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359: 355-65.
-
(2008)
N Engl J Med
, vol.359
, pp. 355-365
-
-
Cooper, D.A.1
Steigbigel, R.T.2
Gatell, J.M.3
-
10
-
-
33847041109
-
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1
-
Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21: 395-402.
-
(2007)
AIDS
, vol.21
, pp. 395-402
-
-
Katlama, C.1
Esposito, R.2
Gatell, J.M.3
-
11
-
-
0038576281
-
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
-
Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-85.
-
(2003)
N Engl J Med
, vol.348
, pp. 2175-2185
-
-
Lalezari, J.P.1
Henry, K.2
O'Hearn, M.3
-
12
-
-
0037849954
-
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
-
Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: 2186-95.
-
(2003)
N Engl J Med
, vol.348
, pp. 2186-2195
-
-
Lazzarin, A.1
Clotet, B.2
Cooper, D.3
-
13
-
-
47949120697
-
Raltegravir with optimized background therapy for resistant HIV-1 infection
-
Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339-54.
-
(2008)
N Engl J Med
, vol.359
, pp. 339-354
-
-
Steigbigel, R.T.1
Cooper, D.A.2
Kumar, P.N.3
-
14
-
-
0037040360
-
A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
-
Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16: 579-88.
-
(2002)
AIDS
, vol.16
, pp. 579-588
-
-
Cohen, C.J.1
Hunt, S.2
Sension, M.3
-
15
-
-
0344593433
-
The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
-
DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5: 41-8.
-
(2000)
Antivir Ther
, vol.5
, pp. 41-48
-
-
Degruttola, V.1
Dix, L.2
D'Aquila, R.3
-
16
-
-
38949152354
-
Highly active antiretroviral therapy- induced liver injury
-
Inductivo-Yu I, Bonacini M. Highly active antiretroviral therapy- induced liver injury. Curr Drug Saf 2008; 3: 4-13.
-
(2008)
Curr Drug Saf
, vol.3
, pp. 4-13
-
-
Inductivo-Yu, I.1
Bonacini, M.2
-
17
-
-
77953531153
-
-
Paper presented at: 15th Conference on Retroviruses and Opportunistic Infections Feb 3-6, 2008, Boston, MA
-
Hardy D, Reynes J, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment- experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies. Paper presented at: 15th Conference on Retroviruses and Opportunistic Infections Feb 3-6, 2008, 2008; Boston, MA.
-
(2008)
Efficacy and Safety of Maraviroc Plus Optimized Background Therapy In Treatment- Experienced Patients Infected With CCR5-tropic HIV-1: 48-week Combined Analysis of The MOTIVATE Studies
-
-
Hardy, D.1
Reynes, J.2
Konourina, I.3
-
18
-
-
34347354196
-
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double- blind, placebo-controlled trial
-
Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double- blind, placebo-controlled trial. Lancet 2007; 370: 39-48.
-
(2007)
Lancet
, vol.370
, pp. 39-48
-
-
Lazzarin, A.1
Campbell, T.2
Clotet, B.3
-
19
-
-
34347327010
-
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double- blind, placebo-controlled trial
-
Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double- blind, placebo-controlled trial. Lancet 2007; 370: 29-38.
-
(2007)
Lancet
, vol.370
, pp. 29-38
-
-
Madruga, J.V.1
Cahn, P.2
Grinsztejn, B.3
-
20
-
-
38649088910
-
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir
-
Lambert-Niclot S, Flandre P, Canestri A, et al. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir. Antimicrob Agents Chemother 2008; 52: 491-6.
-
(2008)
Antimicrob Agents Chemother
, vol.52
, pp. 491-496
-
-
Lambert-Niclot, S.1
Flandre, P.2
Canestri, A.3
|